Skip to main content
logo
Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)
China flag China · Delayed Price · Currency is CNY
6.80
+0.24 (3.66%)
Mar 27, 2026, 4:00 PM EDT

Revenue by Segment

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Gene Therapy CRO Service
85.82M
36.69M36.09M29.35M-
Gene Therapy CRO Service Growth
-
1.67%22.95%--
Gene Therapy CDMO Service
134.94M
101.71M24.83M12.91M-
Gene Therapy CDMO Service Growth
-
309.64%92.31%--
Regenerative Medicine Services
316.96K
----
Biological Agents, Reagents and Others
27.07M
3.91M1.93M1.09M-
Biological Agents, Reagents and Others Growth
-
102.97%77.34%--
Mechanism and Function Service
-
---6.60M
CRO/CDMO/CMO Business
-
---443.32K
Merchandise Sales and Others
-
---2.56M
Pre-Made Virus Service
-
---5.08M
Custom Virus Service
-
---13.14M
Total
248.15M
142.31M62.84M43.35M27.83M
Total Growth
-
126.46%44.98%55.78%-

Revenue by Geography

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Eastern Region
147.55M
72.37M---
South China
26.06M
35.75M---
Northern Region
39.26M
10.46M---
Southwest
8.84M
18.48M---
Others
21.70M
4.89M---
Overseas
1.62M
360.74K---
Total
245.02M
142.31M---
Source: S&P Global Market Intelligence.